000136831 001__ 136831
000136831 005__ 20240229105102.0
000136831 0247_ $$2doi$$a10.1053/j.gastro.2018.03.030
000136831 0247_ $$2pmid$$apmid:29574091
000136831 0247_ $$2pmc$$apmc:PMC6035076
000136831 0247_ $$2ISSN$$a0016-5085
000136831 0247_ $$2ISSN$$a1528-0012
000136831 0247_ $$2altmetric$$aaltmetric:34907484
000136831 037__ $$aDKFZ-2018-01269
000136831 041__ $$aeng
000136831 082__ $$a610
000136831 1001_ $$0P:(DE-He78)f4e98340e600f7411886c21c7b778d36$$aWeigl, Korbinian$$b0$$eFirst author
000136831 245__ $$aGenetic Risk Score Is Associated With Prevalence of Advanced Neoplasms in a Colorectal Cancer Screening Population.
000136831 260__ $$aStanford, Calif.$$bHighWire Press$$c2018
000136831 3367_ $$2DRIVER$$aarticle
000136831 3367_ $$2DataCite$$aOutput Types/Journal article
000136831 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1660208143_9214
000136831 3367_ $$2BibTeX$$aARTICLE
000136831 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000136831 3367_ $$00$$2EndNote$$aJournal Article
000136831 520__ $$aThe presence of specific single nucleotide polymorphisms (SNPs) can be used to calculate an individual's risk for colorectal cancer (CRC), called a genetic risk score (GRS). We investigated whether GRS can identify individuals with clinically relevant neoplasms in a screening colonoscopy population.We derived a GRS based on 48 SNPs associated with CRC, identified in a comprehensive literature search. We obtained genetic data from 1043 participants (50-79 years old) in a screening colonoscopy study in Germany, recruited from 2005 through 2013 (294 with advanced neoplasms, 249 with non-advanced adenoma (NAAs), and 500 without neoplasms). Each participant was assigned a GRS by aggregating their risk alleles (0, 1, or 2). Risk of advanced neoplasms and NAA according to GRS was calculated by multiple logistic regression. Risk advancement periods were calculated. We replicated our findings using data from a subset of the Tennessee Colorectal Polyp Study.An increased GRS was associated with higher prevalence of advanced neoplasms, but not NAAs. Participants in the middle and upper tertiles of GRS had a 2.2-fold and 2.7-fold increase in risk, respectively, of advanced neoplasms compared to those in the lower tertile. Adjusted odds ratios (ORs) were 1.09 (95% confidence interval [CI], 0.76-1.57) for NAA in the middle tertile and 1.05 (95% CI, 0.70-1.55) for NAA in the upper tertile. The ORs were largest for proximal advanced neoplasms for participants in the middle tertile (OR, 3.55; 95% CI 1.85-6.82) and the upper tertile (OR, 3.61; 95% CI 1.84-7.10). The risk advancement period for medium vs low GRS was 13.4 years (95% CI 4.8-22.0) and for high vs low GRS was 17.5 years (95% CI, 7.8-27.3).In a genetic analysis of participants in a CRC screening study in Germany, an increased GRS (based on CRC-associated SNPs) was associated with increased prevalence of advanced neoplasms. These findings might be used in defining risk-adapted screening ages.
000136831 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000136831 588__ $$aDataset connected to CrossRef, PubMed,
000136831 7001_ $$0P:(DE-He78)9af7dea9c075a972fcfa22b583471dae$$aThomsen, Hauke$$b1$$udkfz
000136831 7001_ $$0P:(DE-HGF)0$$aBalavarca, Yesilda$$b2
000136831 7001_ $$aHellwege, Jacklyn N$$b3
000136831 7001_ $$aShrubsole, Martha J$$b4
000136831 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b5$$eLast author
000136831 773__ $$0PERI:(DE-600)1478699-0$$a10.1053/j.gastro.2018.03.030$$gVol. 155, no. 1, p. 88 - 98.e10$$n1$$p88 - 98.e10$$tGastroenterology$$v155$$x0016-5085$$y2018
000136831 909CO $$ooai:inrepo02.dkfz.de:136831$$pVDB
000136831 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f4e98340e600f7411886c21c7b778d36$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000136831 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9af7dea9c075a972fcfa22b583471dae$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000136831 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000136831 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000136831 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000136831 9141_ $$y2018
000136831 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bGASTROENTEROLOGY : 2015
000136831 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000136831 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000136831 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000136831 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000136831 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000136831 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000136831 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000136831 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000136831 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000136831 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000136831 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bGASTROENTEROLOGY : 2015
000136831 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000136831 9201_ $$0I:(DE-He78)G110-20160331$$kG110$$lPräventive Onkologie$$x1
000136831 9201_ $$0I:(DE-He78)C050-20160331$$kC050$$lMolekular-Genetische Epidemiologie$$x2
000136831 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x3
000136831 980__ $$ajournal
000136831 980__ $$aVDB
000136831 980__ $$aI:(DE-He78)C070-20160331
000136831 980__ $$aI:(DE-He78)G110-20160331
000136831 980__ $$aI:(DE-He78)C050-20160331
000136831 980__ $$aI:(DE-He78)L101-20160331
000136831 980__ $$aUNRESTRICTED